Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 1, 2026 → Jul 1, 2027
See other at-risk trials from Mohamed Abdel-Rahman

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027
    • Eligibility criteria expanded, about 6 words
    • Publications: details revised at 1 of 1 entry
  2. Minor 3 versions Re-verified since Oct 23, 2023, no change to tracked fieldsv3-v5
  3. Minor Secondary endpoints revised (5)v2
  4. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1,602 trials monitored
See 70 trials at risk
1,093 trials monitored
See 62 trials at risk
890 trials monitored
See 72 trials at risk
and 2 more diseases
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screening and earlier intervention which would improve the treatment outcome not only for retaining vision but also for overall survival. Similarly in patients with germline BAP1 mutation CM develops in premalignant atypical melanocytic lesions and careful follow up of these patients will improve the outcome of their disease. In addition this study could have impact on the management of patients with personal and/or family history of several other cancers reported in patients with germline BAP1 mutation such as mesothelioma, renal cell carcinoma, cholangiocarcinoma, hepatocellular carcinoma, meningioma and basal cell carcinoma.
Trial Details
NCT Number NCT04792463
Lead Sponsor Mohamed Abdel-Rahman
Conditions
(from sponsor)
Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Related terms Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Cholangiocarcinoma, Melanoma, Mesothelioma, Uveal Melanoma
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov